Galiellio

Galileo Biotech is a biopharmaceutical company specializing in the discovery and development of innovative immunotherapies, with a primary focus on oncology. The company leverages an integrated discovery and engineering platform to generate a pipeline of therapeutic monoclonal antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies. Notably, Galileo Biotech operates a state-of-the-art R&D laboratory and a GMP-certified manufacturing facility in Rio de Janeiro, Brazil, which supports the production of both investigational biologics and in-vitro diagnostic (IVD) products. In August 2023, the company was acquired by Antharis Therapeutics to enhance its global research capabilities and provide internal manufacturing capacity for its expanding portfolio of cancer therapies.